Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Headlines
    1. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Wed, 23 Jul 2014

      as CEO of development-stage biotech Exelixis for 14 years. While we see this as an ..... operations, we think his performance at Exelixis demonstrates a strong understanding of ..... by Stelios Papadopoulos (chairman at Exelixis and Regulus) at Biogen's annual meeting

    2. Traders pile into Exelixis

      Headlines

      Mon, 14 Jul 2014

      Shares of Exelixis ( EXEL +21.8% ) romp on massive turnover of over 33M shares in response to this morning's report of positive results in a Phase

    3. Midday Gainers / Losers

      Headlines

      Mon, 14 Jul 2014

      Top 10 Gainers: GRH +22% . SCOK +20% . KNDI +17% . ULTR +16% . PHX +15% . RADA +13% . EXEL +13% . URS +12% . CBAK +12% . CREG +13% . Top 10 Losers: VISN -14% . FHCO -13% . HLIT -11% . INVT -9% . GIGA -9

    4. Healthcare player Miller believes Roche will gobble up Exelixis

      Headlines

      Mon, 14 Jul 2014

      Feuerstein, David Miller elaborates on his view that Roche ( OTCQX:RHHBY +1.3% ) has a strong incentive to acquire Exelixis ( EXEL +10.7% ) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf

    5. Premarket Gainers / Losers

      Headlines

      Mon, 14 Jul 2014

      Gainers: CREG +20% . PGNX +14% . EXEL +12% . KNDI +11% . URS +8% . APP +7% . DGLY +6% . ICPT +5% . Losers: GTAT -6% . Post your comment!

    6. Combination therapy increases PFS in advanced melanoma patients

      Headlines

      Mon, 14 Jul 2014

      the lower cost and shorter follow-up period. Cobimetinib is being co-developed by Genentech and Exelixis (NASDAQ: EXEL ). Shares of EXEL are up 16% premarket on light volume. Post your comment!

    7. Positive Phase III Results With Roche-Partnered Program; Cometriq Trials Remain Key Driver

      Commentary

      Mon, 14 Jul 2014

      Exelixis and partner Roche have announced positive top-line results for their Phase ..... 50 per share fair value estimate and no-moat, stable trend rating for Exelixis , as we continue to await the more important Phase III results for Cometriq

    8. EXEL - Coming back or a dog?

      Commentary

      Thu, 10 Jul 2014

      Not much news on this one lately, depsite a big drop following Morningstar's latest reaffirmation.  Still a Monringstar 5-star, but lots of shorts and mixed thoughts across traders.  Just bought in at 3 and a quarter, so we'll see.  Speculative at best at this point.  

    9. Two Cancer Stocks Take Shots On Goal: Echo He

      Headlines

      Thu, 19 Jun 2014

      By Life Sciences Report : Oncology is king in biotech. Patients must be put on one drug, and then another, followed by another, as the disease progresses and becomes resistant. Multiple drugs will always be necessary, meaning multiple opportunities for drug companies. In this interview with The ...

    10. Exelixis 1Q Results as Expected; Phase III Prostate Cancer Results in 2014 Remain Key Driver

      Commentary

      Fri, 2 May 2014

      Exelixis reported first-quarter results that were generally consistent with our ..... this year and represent the major catalysts for the firm. In addition, Exelixis ’ partnered asset with Roche, MEK inhibitor GDC-0973 (in combination

    « Prev12345Next »
    Content Partners